Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
CAPECISP
Gastrointestinal - Gastric / Stomach
Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.
An option to ECF, for the palliative treatment of inoperable advanced, metastatic or recurrent adenocarcinoma of the stomach or the gastroesophageal junction
capecitabine
ODB - General Benefit
(capecitabine)
| CISplatin | 80 mg /m² | IV over 2 hours | Day 1 |
| capecitabine | 1000 mg /m² | PO | BID* Days 1 to 14 |
|
(*Total dose 2000 mg/m2/day)
|
|||
REPEAT EVERY 21 DAYS
Until disease progression or unacceptable toxicity occurs; usually given up to 6 cycles due to cumulative cisplatin toxicity
High
No routine prophylaxis for capecitabine
Moderate
Other Supportive Care:
• Standard regimens for Cisplatin premedication and hydration should be followed. Refer to local guidelines.
- Topical emollients (e.g. hand creams, udder balm) may ameliorate the manifestations of hand-foot syndrome in patients receiving capecitabine.
- Supportive care should be provided, including loperamide for diarrhea.
Also refer to CCO Antiemetic Recommendations.
Doses should be modified according to the protocol by which the patient is being treated. The following recommendations have been adapted from clinical trials or product monographs and could be considered.
Use capecitabine with extreme caution in patients with partial DPD deficiency; reduce the initial dose substantially, monitor frequently and adjust the dose for toxicity as recommended in the dosage with toxicity section. In patients with unrecognized DPD deficiency, acute, life-threatening toxicity may occur; discontinue if acute grade 2-4 toxicity develops.
Dosage with toxicity
|
Worst Toxicity in Previous Cycle |
Dose for this cycle (% previous dose)*
|
|
Grade 4 platelets, grade 4 ANC ≥ 5 days, thrombocytopenic bleeding or febrile neutropenia |
75%
|
|
Grade 2 neurotoxicity /ototoxicity |
75%
|
|
Grade 3 or 4 neurotoxicity/ototoxicity
|
Discontinue
|
|
Other grade 3 non-hematologic/organ |
75%
|
| Worst Toxicity in Previous Cycle (Continued) | Dose for this cycle (% previous dose)* |
|
Other grade 4 non-hematologic/organ
|
Discontinue
|
|
Hemolysis, optic neuritis, arterial thromboembolism, severe hypersensitivity reactions |
Discontinue
|
|
* Do not retreat until platelets ≥100 x 109/L, ANC ≥ 1.5 x 109/L, toxicity has recovered to ≤ grade 2 (grade 1 for neurotoxicity) and creatinine ≤ grade 1. |
|
Dose Modifications: Capecitabine
|
Toxicity
|
Action During a Course of Therapy
|
Dose Adjustment for Next Cycle (% of starting dose)
|
|
Grade 1
|
Maintain dose level
|
Maintain dose level
|
|
Grade 2
1st appearance
2nd appearance
3rd appearance
4th appearance
|
Interrupt until resolved to grade 0-1
Interrupt until resolved to grade 0-1
Interrupt until resolved to grade 0-1 Discontinue treatment permanently
|
100%
75%
50%
--
|
|
Grade 3
1st appearance
2nd appearance
3rd appearance OR any evidence of Stevens-Johnson syndrome or Toxic Epidermal Necrolysis |
Interrupt until resolved to grade 0-1
Interrupt until resolved to grade 0-1
Discontinue treatment permanently
|
75%
50%
--
|
|
Grade 4
1st appearance, including SJS, TENS, OR
cardiotoxicity OR acute renal failure
2nd appearance
|
Discontinue permanently Discontinue permanently
|
Discontinue
or
50%
--
|
Hepatic Impairment
No adjustment required for cisplatin.
- Use dose modification table above for increases in bilirubin.
- In patients with mild to moderate hepatic impairment due to liver metastases exposure is increased, but no dose adjustment is necessary, although caution should be exercised.
- The use of capecitabine in patients with severe hepatic impairment has not been studied.
Renal Impairment
|
Creatinine Clearance (mL/min)
|
Cisplatin (% previous dose)
|
Capecitabine (% previous dose)
|
|
61-80
|
100%
|
|
|
51-60
|
75%
|
100% with close monitoring
|
|
46-50
|
75%
|
75%; use with caution
|
|
30-45
|
50%
|
75%; use with caution
|
|
<30
|
Discontinue
|
CONTRAINDICATED
|
| Most Common Side Effects |
Less Common Side Effects, but may be |
|
|
Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.
Recommended Clinical Monitoring
- Audiogram; as clinically indicated
- CBC; baseline and regular
- Electrolytes, including magnesium, sodium, potassium, phosphate and calcium; baseline and regular
- Baseline and regular liver & renal function tests
- INR or PT; baseline and regular if on anticoagulants
- Clinical toxicity assessment for diarrhea, dehydration infection, bleeding, stomatitis, rash, hand-foot syndrome, nausea/vomiting, neurotoxicity, ototoxicity, cardiac, thromboembolism and other GI toxicity; at each visit
-
Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
back to top
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376(9742): 687-97.
Capecitabine and cisplatin drug monographs, Cancer Care Ontario.
Kang YK, Kang WK, Shin D, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20(4):666-73.
May 2019 Updated emetic risk category
Regimen Abstracts
A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.
Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.
Regimen Monographs
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.